Chris has over 30 years in the pharmaceutical and professional services sector and most recently worked at the global strategic marketing consultancy Osprey Health Consulting.
His experience includes periods leading organisations, acquisition teams, reinvigorating distressed businesses and as a strategic marketing consultant to the pharmaceutical industry. At Johnson and Johnson, Belgium, Chris launched the anti-psychotic drug Risperdal. Then in the US, while at Thomson Reuters, he turned around three underperforming businesses, was a member of the healthcare acquisitions team and became the in-house specialist in assessing professional services firms. In addition, Chris has created a highly successful US operation for a medical communications agency, a novel EU operation for a US corporation and has consulted with various professional services firms across the healthcare sector.
Having published numerous articles, mostly on the topics of strategic marketing and the leadership of professional services firms, Chris has a special interest in the growth and development of SMEs and has worked closely with a number of organisations in developing sustainable growth, people and leadership development programs.